LUTATHERA (PRRT) – NETTER 2 Clinical Trial for Grade 2/Grade 3 Patients Advanced GEP-NET (NETTER-2)

Translate
Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 19,443 other subscribers.

Brief Summary

The NETTER-1 trials led to the approval of Lu177 (or Lutathera), more commonly known in the community as Peptide Receptor Radio Therapy (PRRT).  This led to an explosion of availability across the world but many gaps in service remain.

Many PRRT spin off trials are in the pipeline looking at different types of PRRT, mainly using slightly different radionuclides and techniques.  However, NETTER-2 builds on the success of the approved version formally known as Lutathera.

The aim of NETTER-2 is to determine if Lutathera in combination with long-acting octreotide prolongs PFS in GEP-NET patients with high proliferation rate tumors (G2 and G3), when given as a first line treatment compared to treatment with high dose (60 mg) long-acting octreotide. Somatostatin analog (SSA) naive patients are eligible, as well as patients previously treated with SSAs in the absence of progression. This is a phase 3 trial that will be hoping for 222 participants at multiple locations.

This is an exciting trial because there are already data produced indicating that PRRT can be used on high grade tumours providing they have sufficient and efficient somatostatin receptors and a Ki67 of less than 55%.  2019 Updated data for Grade 3 Neuroendocrine Neoplasms: “Compared to studies evaluating the efficacy of chemotherapy for NEN patients with a Ki-67 index less than or equal to 55 percent, PRRT has a longer overall survival rate–22 months versus 14 months,” the researchers pointed out. “These results suggest that PRRT, rather than chemotherapy, may be a superior first-line therapeutic option in selected patients with a high level of SSTR expression and a Ki-67 index of less than or equal to 55%.”  Read more here.

The trial is taking place in USA (Texas), UK, Italy, Spain and France. The first patient was treated in March 2020 (click here to see this update).  Important to read the criteria section if this trial interests you. Clinical Trials document here.

In the meantime, read more about Lutathera (PRRT) by clicking here.

This looks like a very exciting development.

General Clinical Trials Disclaimer

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact.  If you need questions, the articles here is very useful Questions to Ask About Clinical Trials | Cancer.Net

The inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan. 

 
 

Thanks for reading.

Ronny

I’m also active on Facebook. Like my page for even more news. Help me build up my new site here – click here and ‘Like’

Sign up for my newsletters – Click Here

Disclaimer

My Diagnosis and Treatment History

Follow me on twitter

Check out my online presentations

Check out my WEGO Health Awards

Like my new awareness page – click here or on the photo.  (Like rather than follow please!)

Check out my Glossary of Terms – click here

patients included

Please Share this post for Neuroendocrine Cancer awareness and to help another patient

 
 
 
Facebook
Twitter
Pinterest
WhatsApp
Email

RonnyAllan.NET – Summary of January 2023 – Ronny Allan – Living with Neuroendocrine Cancer

Summary Great start to 2023 and I thank those who continue to support my social media and this blog.  I’m keen to hear any suggestions

Read More »

Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies (incl NET)

Trial Summary This interesting trial is a multi-cancer effort including NET.  The phase I clinical trial of Procaspase Activating Compound-1 (PAC-1), a drug that spurs

Read More »

Dustin Diamond

I’m behind the curve on this one after being ahead on celebrities such as Steve Jobs, Aretha Franklin, Wilko Johnson and Olivia Williams.  But in

Read More »

Neuroendocrine tumors are uncommon but definitely not rare

USA finally commits  UK and Australian figures recently confirmed that Neuroendocrine Cancer is the 10th and 7th most common cancer type.  It was great to

Read More »

Cancer Ablation

What is Cancer Ablation? This is a minimally invasive surgical method to treat solid cancers. Special probes are used to “burn” or “freeze” cancers. Computed

Read More »

Lactose intolerance – the NET Effect

Background   When I cast my mind back to my very first surgery, I remember asking my Oncologist what I could do to put on weight. 

Read More »

EUS Guided Ablation for small pancreatic NETs (Less than 2cm)

To burn or not to burn? I once wrote a post about Pancreatic NET “to cut or not to cut”.  You can read that here. 

Read More »

RonnyAllan.NET – a review of 2022

Review In 2022, my pet project (my blog) hit 2 million views in early November – that was a major boost.  It takes 3-4 years to get

Read More »

RonnyAllan.NET – Summary of December 2022

Summary December is always the quietest month of the year, no surprise why!  However, the top 10 below is somewhat surprising, I guess some posts

Read More »

4 thoughts on “LUTATHERA (PRRT) – NETTER 2 Clinical Trial for Grade 2/Grade 3 Patients Advanced GEP-NET (NETTER-2)

  • David

    Hi Ronny a concern of the NETTER 2 trial by leading experts is that they would never give 60mg octreotide to G3 patients as first line treatment. For this trial to be ethical and really have a comparative arm it should compare PRRT with standard of care which is Chemotherapy. It may be very hard to recruit to ethically?

  • Carole Way

    Hi Ronny
    Just an update. Spoke to my NET nurse and UHCW at Coventry are now able to offer PRRT, so perhaps you could check this is correct and add to the UK list. Cheers.

I love comments - feel free!

%d bloggers like this: